Skip to content
Evofem Biosciences, Inc.
About Us
Mission
Management
Board of Directors
Saundra Pelletier
KIM P. KAMDAR, Ph.D.
Tony O’Brien
Lisa Rarick, MD
Colin Rutherford
Our Products
phexx
®
Solosec
®
Publications
PHEXX
SOLOSEC
Investors
Investor Overview
Why Invest
Events & Presentations
Press Releases
Stock Information
Financial Information
Quarterly Results
SEC Filings
Corporate Governance
Committee Composition
Board of Directors
Charters + Code of Ethics
Investor Resources
Investor Email Alerts
Information Request Form
Investor Contact
Investor FAQs
Contact
Investor Contact
Media Contact
General Contact
Careers
Compliance with Vaginal PH Modulator in the Phase 3 Ampower Contraceptive Trial
Post navigation
Previous:
Assessing the Understandability and Importance of Patient Reported Outcomes Impacting Adherence and Outcomes of a Non-Hormonal Vaginal Microbicide to Protect Against Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (GC)
Next:
Pregnancy Intendedness with Vaginal PH Modulator: Results from the Phase 3 Ampower Trial
Back
to
Top
